Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Harvard Bioscience, Inc. before investing.

In this article, we go over a few key elements for understanding Harvard Bioscience, Inc.’s stock price such as:

• Harvard Bioscience, Inc.’s current stock price and volume
• Why Harvard Bioscience, Inc.’s stock price changed recently
• Upgrades and downgrades for HBIO from analysts
• HBIO’s stock price momentum as measured by its relative strength

About Harvard Bioscience, Inc. (HBIO)

Before we jump into Harvard Bioscience, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Want to learn more about Harvard Bioscience, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Harvard Bioscience, Inc..

Harvard Bioscience, Inc.’s Stock Price as of Market Close

As of February 21, 2025, 4:00 PM, CST, Harvard Bioscience, Inc.’s stock price was $0.990.

Harvard Bioscience, Inc. is down 16.1% from its previous closing price of $1.180.

During the last market session, Harvard Bioscience, Inc.’s stock traded between $0.944 and $1.140. Currently, there are approximately 43.61 million shares outstanding for Harvard Bioscience, Inc..

Harvard Bioscience, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Harvard Bioscience, Inc. Stock Price History

Harvard Bioscience, Inc.’s (HBIO) price is currently down 42.11% so far this month.

During the month of February, Harvard Bioscience, Inc.’s stock price has reached a high of $1.700 and a low of $0.944.

Over the last year, Harvard Bioscience, Inc. has hit prices as high as $4.700 and as low as $1.160. Year to date, Harvard Bioscience, Inc.’s stock is down 53.08%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Harvard Bioscience, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of February 20, 2025,, no analysts have changed their rating of Harvard Bioscience, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Harvard Bioscience, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Harvard Bioscience, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Harvard Bioscience, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Harvard Bioscience, Inc. (HBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Harvard Bioscience, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 20, 2025, Harvard Bioscience, Inc. has a weighted four-quarter relative price strength of -33.80%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how Harvard Bioscience, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Harvard Bioscience, Inc. Stock Price: Bottom Line

As of February 21, 2025, Harvard Bioscience, Inc.’s stock price is $0.990, which is down 16.1% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Harvard Bioscience, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.